Jin Medical International Ltd. designs and manufactures wheelchairs and living aids products.
| Revenue (TTM) | $19.73M |
| Gross Profit (TTM) | $6.17M |
| EBITDA | 657,350 |
| Operating Margin | -7.23% |
| Return on Equity | 4.02% |
| Return on Assets | 0.50% |
| Revenue/Share (TTM) | $2.52 |
| Book Value | $3.79 |
| Price-to-Book | 0.87 |
| Price-to-Sales (TTM) | 1.37 |
| EV/Revenue | 0.867 |
| EV/EBITDA | 23.45 |
| Quarterly Earnings Growth (YoY) | -32.00% |
| Quarterly Revenue Growth (YoY) | -9.70% |
| Shares Outstanding | $6.83M |
| Float | $1.94M |
| % Insiders | 8.06% |
| % Institutions | 0.03% |
Volatility is currently expanding
CHANGZHOU, China, Aug. 4, 2026 /PRNewswire/ -- JIN MEDICAL INTERNATIONAL LTD. (Nasdaq: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated entities, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment in China, today announced its unaudited financial results for the six months ended March 31, 2026.
CHANGZHOU, China, April 7, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated entities, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment, today announced that it has received written notification from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ZJYL and any ticker you trade — then tracks every position and per-strategy win rate.
